Recruiting

Observational Study

Sponsor:

Target PharmaSolutions, Inc.

Code:

NCT07748169

Conditions

Vitiligo

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Conditions

Vitiligo

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa (HS)

Study ID

NCT07748169

Start date

Aug 1, 2026

Status verified date

Jul, 2026

Completion date

Aug 3, 2041

Anticipated

Primary completion date

Aug 3, 2041

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
  • Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.

Exclusion Criteria:

  • Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Study Design

Enrollment

2000000 participants

Anticipated

Interventions and Outcome Measures

Arms

Disease Cohort

Adult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface.

Engaged Cohort

Adult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions.

  • Informed consent is required for all participants in an Engaged Cohort.
  • Willing to complete required Engaged Cohort activities.

Primary outcome measure

  • To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease [ Time Frame: 15 years ]
  • To characterize the natural history of disease in patients with dermatologic disease from various etiologies [ Time Frame: 15 years ]
  • To establish learning health networks focused on quality of care for patients [ Time Frame: 15 years ]

Central Contacts and Locations

Central contacts

Lynda Lee Burch

9842340268lburch@pedestalhealth.com

Danisha Devane

9842340268ddevane@pedestalhealth.com

Locations

Wake Forest University Health Science

Recruiting

Winston-Salem, North Carolina, United States, 27157

Contacts

Irma Richardson

336-716-7740Irma.Richardson@advocatehealth.org

Principal Investigator:

Steven Feldman, MD

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Principal Investigator:

Joel Gelfand, MD

Medical University of South Carolina

Recruiting

Charleston, South Carolina, United States, 29407

Contacts

Patrick Cote

843-792-3746cotp@musc.edu

Courtney Rowley

843-792-9784rowle@musc.edu

Principal Investigator:

Lara Wine-Lee, MD

More Information

Sponsor

Target PharmaSolutions, Inc.

Last update posted

Aug 5, 2026

Last verified

Jul, 2026

Keywords

  • Dermatologic Disease
  • DERM+

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-05. This information was provided to ClinicalTrials.gov by Target PharmaSolutions, Inc. on 2026-08-05.